These are the upcoming stock splits for the week of March 3 to March 7, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split.
In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In this case, too, the market cap is maintained as the share price increases following the reverse stock split.
Companies often undertake stock splits to improve the liquidity of the common shares and make them more affordable for retail investors. Let’s look quickly at the upcoming stock splits for the week.
Eastside Distilling, Inc. (BLNE) – Eastside Distilling manufactures and markets hand-crafted spirits, including Tequilas, Whiskeys, Rum, and Vodkas. On February 10, the company’s board of directors approved a one-for-ten reverse stock split of its common shares. BLNE stock is expected to start trading on a split-adjusted basis on March 6.
Lichen China Ltd. (LICN) – Lichen China Ltd. is a financial and taxation services provider in China. LICN is registered as a holding company in the Cayman Islands and operates its business through subsidiaries in the PRC (People’s Republic of China) region. On February 27, LICN announced a one-for-200 reverse stock split for its Class A and Class B common shares, to be effective on March 3. The split is being undertaken to regain compliance with Nasdaq’s minimum bid price requirement of $1 per share. At the same time, LICN announced that it is changing its name to Lichen International Limited.
China Liberal Education Holdings (CLEU) – China Liberal Education Holdings is an educational services provider. CLEU offers technological consulting to its partner universities to enhance their teaching, operating, and management environment. Thus, helping in creating “smart campuses.” On February 26, CLEU announced a one-for-80 reverse stock split of its common stock, to be effective on March 3.
Starbox Group Holdings Ltd. (STBX) – Malaysia-based Starbox Group Holdings is a technology-powered company. STBX seeks to create a cash rebate, digital advertising, and payment solution business ecosystem to help micro, small, and medium enterprises develop in-house data management system for effective marketing. On February 27, STBX announced a one-for-10 reverse stock split of its Class A and Class B common shares as well as its Preferred shares to regain compliance with Nasdaq’s listing requirements. STBX stock is expected to start trading on a split-adjusted basis on March 3.
Edible Garden AG, Inc. (EDBL) – Edible Garden is a CEA (controlled environment agriculture) farming company. EDBL produces locally grown organic leafy greens and herbs using its state-of-the-art greenhouses and processing facilities in the U.S. On February 27, EDBL announced a one-for-25 reverse stock split of its common stock. EDBL stock is expected to start trading on a split-adjusted basis on March 3.
Venus Concept (VERO) – Venus Concept is a Canadian company specializing in the aesthetic intelligence market. Venus Concept is a global medical aesthetic company offering a wide variety of minimally invasive and non-invasive medical aesthetic and hair restoration technologies. On February 27, VERO announced a one-for-11 reverse stock split of its common stock, to boost its per share trading price and regain compliance with Nasdaq’s listing requirements. VERO stock is expected to start trading on a split-adjusted basis on March 4.
Biotron Limited (BITRF) – Biotron Limited is an Australia-based biotechnology company. Biotron’s lead drug candidate, BIT225, is being developed for the treatment of HIV-1 and Hepatitis C virus infections. Biotron recently announced a one-for-one rights issue, with the entitlement trading period beginning on March 5. The company seeks to raise roughly $2.7 million through the renounceable pro-rata entitlement offer. The proceeds shall be utilized for drug commercialisation activities, patent renewals, to fund the ongoing research in the Hepatitis B studies, and working capital.
To find more information about historical and upcoming stock splits, visit the TipRanks Stock Splits Calendar.